An article in the New York Times is the latest to highlight the safety risks associated with recently approved new treatments for Alzheimer’s disease, lecanemab and donanemab. Being a carrier…
더 읽어보기
Message from the Director Dear Friends of UCI MIND, This summer, we lost our founder, Dr. Carl Cotman. Under Dr. Cotman’s leadership, UCI became an independent ADRC in 2000. He…
더 읽어보기
Breaking the Tyranny of Treatment: A New Perspective on Alzheimer’s Care The post Dr. Joshua Grill and colleague from Penn publish essay on clinical implications of new drugs appeared first…
더 읽어보기
This Hispanic Heritage Month, we proudly recognize the invaluable contributions of our faculty, staff, community partners, and supporters who are dedicated to addressing Alzheimer’s disease and related dementias in the…
더 읽어보기
AlzForum, the popular online publication for Alzheimer’s researchers, published a summary of recent advances from the MODEL-AD teams and highlighted the work of the principal investigators at UCI, Drs. Kim…
더 읽어보기